GS-6624: Phase II started

Last quarter, Gilead began a double-blind, U.S. Phase II trial to compare 200 and 700 mg GS-6624 in combination with FOLFIRI vs. FOLFIRI plus placebo in 265 patients who progressed after first-line ox...